Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan.
Clin J Am Soc Nephrol. 2011 Mar;6(3):630-9. doi: 10.2215/CJN.06730810. Epub 2010 Nov 4.
Gitelman's syndrome (GS) is an autosomal recessive renal tubular disorder caused by mutations in the SLC12A3 gene encoding the thiazide-sensitive Na(+)-Cl(-) cotransporter (NCC). Despite meticulous sequencing of genomic DNA, approximately one-third of GS patients are negative or heterozygotes for the known mutations.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Because blood leukocytes express NCC mRNA, we evaluate whether deep intronic mutations contribute to GS patients with uniallelic or undetectable SLC12A3 mutations. Twenty-nine patients with GS (men/women = 16/13), including eight negative and 21 uniallelic SLC12A3 mutations from 19 unrelated families, and normal controls were enrolled in an academic medical center. Analysis of cDNA from blood leukocytes, sequencing of the corresponding introns of genomic DNA for abnormal transcript, and analysis of NCC protein expression from renal biopsy were performed.
We identified nine Taiwan aboriginal patients carrying c.1670-191C→T mutations in intron 13 and 10 nonaboriginal patients carrying c.2548+253C→T mutations in intron 21 from 14 families (14/19). These two mutations undetected in 100 healthy subjects created pseudoexons containing new premature termination codons. Haplotype analysis with markers flanking SLC12A3 revealed that both mutations did not have founder effects. Apical NCC expression in the DCT of renal tissue was markedly diminished in two patients carrying deep intronic mutations.
Deep intronic mutations in SLC12A3 causing defective NCC expression can be identified with the RNA-based approach in patients with GS. c.1670-191C→T and c.2548+253C→T are hot spot mutations that can be screened in GS patients with uniallelic or negative SLC12A3 mutations.
Gitelman 综合征(GS)是一种常染色体隐性遗传性肾小管疾病,由编码噻嗪敏感的 Na(+)-Cl(-) 共转运体(NCC)的 SLC12A3 基因突变引起。尽管对基因组 DNA 进行了细致的测序,但大约三分之一的 GS 患者的已知突变呈阴性或为杂合子。
设计、环境、参与者和测量:由于血液白细胞表达 NCC mRNA,我们评估是否深内含子突变导致具有单等位基因或无法检测到 SLC12A3 突变的 GS 患者。从 19 个无关的家庭中招募了 29 名 GS 患者(男性/女性=16/13),包括 8 名阴性和 21 名单等位基因 SLC12A3 突变患者,以及正常对照者。从血液白细胞中提取 cDNA,对基因组 DNA 中相应内含子进行异常转录测序,并从肾活检中分析 NCC 蛋白表达。
我们在 14 个家庭(14/19)中发现了 9 名台湾原住民患者携带 13 号内含子中的 c.1670-191C→T 突变,以及 10 名非原住民患者携带 21 号内含子中的 c.2548+253C→T 突变。这两种突变在 100 名健康对照者中未被检测到,产生了含有新的提前终止密码子的假外显子。用侧翼 SLC12A3 的标记物进行的单倍型分析表明,这两种突变均没有起源效应。携带深内含子突变的两名患者的肾组织 DCT 顶端 NCC 表达明显减少。
通过基于 RNA 的方法可以在 GS 患者中识别导致 NCC 表达缺陷的 SLC12A3 深内含子突变。c.1670-191C→T 和 c.2548+253C→T 是可以在具有单等位基因或阴性 SLC12A3 突变的 GS 患者中进行筛选的热点突变。